Evidence mapPaperPMID 40591096Full record

ArticleJournal of patient-reported outcomes2025

Qualitative exploration of women's experiences of vasomotor symptoms to support the content validity of patient-reported outcomes.

Claudia Haberland, Melissa Barclay, Sophie Whyman, Asha Lehane, Adam Gater, Christoph Gerlinger, Christian Seitz, Maja Francuski, Nils Schoof, Andrew Trigg and 1 more

Abstract read
In one paragraph

Article in Journal of patient-reported outcomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Claudia HaberlandBayer AG, Berlin, Germany. claudia.haberland@bayer.com.
Melissa BarclayAdelphi Values, Cheshire, UK.
Sophie WhymanAdelphi Values, Cheshire, UK.
Asha LehaneAdelphi Values, Cheshire, UK.
Adam GaterAdelphi Values, Cheshire, UK.
Christoph GerlingerBayer AG, Berlin, Germany.
Christian SeitzBayer AG, Berlin, Germany.
Maja FrancuskiBayer AG, Berlin, Germany.
Nils SchoofBayer AG, Berlin, Germany.
Andrew TriggMedical Affairs Statistics, Bayer plc, Reading, UK.
Helena BradleyAdelphi Values, Cheshire, UK. helena.bradley@adelphivalues.com.ORCID http://orcid.org/0000-0002-7077-2183

Funding

Bayer Bayer
6 · The paper itself

Abstract

backgroundFrequency and severity of vasomotor symptoms (VMS; hot flashes) associated with menopause significantly impact women's health-related quality of life (HRQoL). Treatment benefit in VMS clinical trials is assessed using patient-reported outcome (PRO) measures, which must demonstrate evidence of content validity. This research aimed to establish a conceptual model in VMS and evaluate content validity of the Hot Flash Daily Diary (HFDD), PROMIS Sleep Disturbance Short Form 8b (PROMIS SD SF 8b), and Menopause-Specific Quality of Life (MENQOL) questionnaire for use in VMS clinical trials.

methodsTargeted searches were conducted to identify qualitative literature documenting women's VMS experiences. Qualitative concept elicitation (CE) and cognitive interviews (CI) were then conducted with 20 US participants experiencing VMS (n = 10 postmenopause; n = 10 AET-treated). Literature and CE findings were used to develop a conceptual model and confirm conceptual coverage of PRO measures selected for assessing efficacy in VMS clinical trials. CIs assessed the content validity of PRO measures.

resultsFindings from the literature and CE interviews informed a conceptual model depicting women's experiences of VMS. Thirty-three symptom concepts were identified with key symptoms including sweating, cold sweats/chills and tiredness/fatigue. Impacts of VMS on HRQoL were categorized into seven domains: sleep, emotional wellbeing, activities of daily living, social wellbeing, work/education, cognitive and physical functioning. The concepts assessed by the HFDD (VMS severity and frequency), PROMIS SD SF 8b (sleep disturbance) and MENQOL (menopause-related quality of life) aligned with those endorsed by women as relevant to their VMS experience. Instructions, recall periods and response options of the measures were understood. A reduction of one moderate or one severe hot flash in 24-hours (assessed by the HFDD) was considered a meaningful improvement by participants. Similar observations were made across study samples.

conclusionsFindings provide detailed insights into women's experience of VMS, supporting the development of a conceptual model and assessment of conceptual coverage of selected PRO measures. Content validity of the HFDD, PROMIS SD SF 8b, and MENQOL for use in VMS clinical trials was supported. CI results suggest that a reduction of one moderate or one severe hot flash in 24-hours is meaningful to women with VMS.

Indexed as

Hot FlashesMenopausePatient Reported Outcome MeasuresQuality of LifeAdultFemaleHumansMiddle AgedQualitative ResearchReproducibility of ResultsSurveys and QuestionnairesConceptual modelContent validityHot flashesMeaningful changeMenopausePatient-reported outcomeVasomotor symptoms

Identifiers

PMID40591096
PMCPMC12214113

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.